Renal cell carcinoma: Recent progress and future directions

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5189-5195

  Mulders, Peter ^a   Figlin, Robert ^a   DeKernion, Jean B ^a   Wiltrout, Robert ^b   Linehan, Marston ^b   Parkinson, David ^c   DeWolf, William ^d   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Biochemical Parasitology Unit Animal Health Sector Novartis Inc   (Switzerland)

^d Harvard Beth Israel Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CANCER ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; CANCER RISK; CONFERENCE PAPER; DENDRITIC CELL; GENE THERAPY; IMMUNE RESPONSE; KIDNEY CARCINOMA; METASTASIS; MOLECULAR GENETICS; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DIET; SMOKING;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; CANCER VACCINES; CARCINOMA, RENAL CELL; FORECASTING; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS;

EID: 0030695173     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. United States Department of Health and Human Services, USPHS, NIH. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute, 1993.
2. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 46: 5-27, 1996.
3. Chow, W. H., Gridley, G., McLaughlin, J. K., Mandel, J. S., Wacholder, S., Blot, W. J., Niwa, S., and Fraumeni, J. F., Jr. Protein intake and risk of renal cell cancer. J. Natl. Cancer Inst., 86: 1131-1139, 1994.
4. McLaughlin, J. K., Chow, W. H., Mandel, J. S., Mellemgaard, A., McCredie, M., Lindblad, P., Schlehofer, B., Pommer, W., Niwa, S., and Adami, H. O. International renal cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int. J. Cancer, 63: 216-221, 1995.
5. McLaughlin, J. K., Lindblad, P., Mellemgaard, A., McCredie, M., Mandel, J. S., Schlehofer, B., Pommer, W., and Adami, H. O. International renal cell cancer study. I. Tobacco use. Int. J. Cancer, 60: 194-198, 1995.
6. Golimbu, M., Joshi, P., Sperber, A., Tessler, A., Al-Askari, S., and Morales, P. Renal cell carcinoma: survival and prognostic factors. Urology, 27: 291-301, 1986.
7. deKernion, J. B., Ramming, K. P., and Smith, R. B. The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol., 120: 148-152, 1978.
8. Franklin, J., Dorey, F., Gitlitz, B., deKernion, J., Figlin, R., and Belldegrun, A. Cytoreductive nephrectomy in 63 consecutive patients who received adoptive immunotherapy for advanced renal cell carcinoma. J. Urol., 155: 500A, 1996.
9. Belldegrun, A., and deKernion, J. B. Renal tumors. In: P. Walsh (ed.), Campbell's Urology. Philadelphia: W. B. Saunders, 1997.
10. Gerharz, C. D., Moll, R., Storkel, S., Ramp, U., Thoenes, W., and Gabbert, H. E. Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. Am. J. Pathol., 142: 851-859, 1993.
11. Hewitt, S. M., Hamada, S., McDonnell, T. J., Rauscher, F. J., III, and Saunders, G. F. Regulation of the proto-oncogenes bcl-2 and c-myr by the Wilms' tumor suppressor gene WT1. Cancer Res., 55: 5386-5389, 1995.
12. Linehan, W. M., Lerman, M. I., and Zbar, B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. J. Am. Med. Assoc., 273: 564-570, 1995.
13. Poston, C. D., Jaffe, G. S., Lubensky, I. A., Solomon, D., Zbar, B., Linehan, W. M., and Walther, M. M. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J. Urol., 153: 22-26, 1995.
14. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, H., Wei, M. H., Chen, F., Glenn, G., Choyke, P., Walther, M. M., Weng, Y., Duan, D. R., Dean, M., Glavac, D., Richards, F. M., Crossey, P. A., Ferguson-Smith, M. A., Le Paslier, D., Chumakov, I., Cohen, D., Chinault, A. C. Maher, E. R., Linehan, W. M., Zbar, B., and Lerman, M. I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.
15. Lubensky, I. A., Gnarra, J. R., Bertheau, P., Walther, M. M., Linehan, W. M., and Zhuang, Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol., 149: 2089-2094, 1996.
16. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F. M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., and Linehan, W. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7: 85-90, 1994.
17. Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, Y., Kitamura, H., Latif, F., Zbar, B., Lerman, M. I., and Yao, M. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res., 54: 2852-2855, 1994.
18. Herman, L G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., Linehan, W. M., and Baylin, S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.
19. Lee, S., Chen, D. Y., Humphrey, J. S., Gnarra, J. R., Linehan, W. M., and Klausner, R. D. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. USA, 93: 1770-1775, 1996.
20. Duan, D. R., Pause, A., Burgess, W. H., Aso, T., Chen, D. Y., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., and Klausner, R. D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (Washington DC), 269: 1402-1406, 1995.
21. Kibel, A., Iliopoulos, O., DeCaprio, J. A., and Kaelin, W. G., Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science (Washington DC), 209: 1444-1446, 1995.
22. Pause, A., Lee, S., Worrell, R. A., Chen, D. Y., Burgess, W. H., Linehan, W. M., and Klausner, R. D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA, 94: 2156-2161, 1997.
23. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W. M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA, 93: 10589-10594, 1996.
24. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr., and Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA, 93: 10595-10599, 1996.
25. Zbar, B., Tory, K., Merino, M., Schmidt, L., Glenn, G., Choyke, P., Walther, M. M., Lerman, M., and Linehan, W. M. Hereditary papillary renal cell carcinoma. J. Urol., 151: 561-566, 1994.
26. Zbar, B., Glenn, G., Lubensky, I., Choyke, P., Walther, M. M., Magnusson, G., Bergerheim, U. S., Pettersson, S., Amin, M., and Hurley, K. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J. Urol., 153: 907-912, 1995.
27. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C. Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M., Linehan, W. M., and Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
28. Kakehi, Y., Kanamaru, H., Yoshida, O., Ohkubo, H., Nakanishi, S., Gottesman, M. M., and Pastan, I. Measurement of multidrug-resistance messenger RNA in urogenital cancers: elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J. Urol., 139: 862-865, 1988.
29. Yagoda, A., Abi-Rached, B., and Petrylak, D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin. Oncol., 22: 42-60, 1995.
30. Gitlitz, B. J., Belldegrun, A., and Figlin, R. A. Immunotherapy and gene therapy. Semin. Urol. Oncol., 14: 237-243, 1996.
31. Rosenberg, S. A. Adoptive immunotherapy for cancer. Sci. Am., 262: 62-69, 1990.
32. Wigginton, J. M., Kuhns, D. B., Back, T. C., Brunda, M. J., Wiltrout, R. H., and Cox, G. W. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res., 56: 1131-1136, 1996.
33. Mulders, P., Tso, C., Kaboo, R., Frand, S., Michel, K., Figlin, R., deKernion, J., and Belldegrun, A. Multi-antigen loaded dendritic cells as potent inducers of a specific anti-tumor response; a novel approach to adoptive immunotherapy for renal cell carcinoma. J. Urol., 157: 109, 1997.
34. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
35. Bhardwaj, N., Seder, R. A., Reddy, A., and Feldman, M. V. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J. Clin. Invest., 98: 715-722, 1996.
36. Brandle, D., Brasseur, F., Weynants, P., Boon, T., and Van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183: 2501-2508, 1996.
37. Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., and Rosenberg, S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., 181: 799-804, 1995.
38. Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T., Groettrup, M., Sijts, A., Mengede, E., Kloetzel, P. M., Neefjes, J., Koszinowski, U., and Melief, C. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation, resulting in lack of antigen presentation. Immunity, 5: 115-124, 1996.
39. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., and Melief, C. J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol., 156: 3308-3314, 1996.
40. Yang, J. C., Topalian, S. L., Parkinson, D., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., White, D. E., Steinberg, S. M., Cole, D. J., Kim, H. I., Levin, R., Guleria, A., MacFarlane, M. P., White, R. L., Einhorn, J. H., Seipp, C. A., and Rosenberg, S. A. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol., 12: 1572-1576, 1994.
41. Wirth, M. P. Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am., 20: 283-295, 1993.
42. Motzer, R. J., Schwanz, L., Law, T. M., Murphy, B. A., Hoffman, A. D., Albino, A. P., Vlamis, V., and Nanus, D. M. Interferon α-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a Phase II trial and interactions in vitro. J. Clin. Oncol., 13: 1950-1957, 1995.
43. Ellerhorst, J. A., Kilbourn, R. G., Amato, R. J., Zukiwski, A. A., Jones, E., and Logothetis, C. J. Phase II trial of low-dose γ-interferon in metastatic renal cell carcinoma. J. Urol., 152: 841-845, 1994.
44. Small, E. J., Weiss, G., Dutcher, J., Walther, P., Johnson, D., Wilding, G., Kuzel, T., Kralik, C., and Paton, V. Preliminary results from a multicenter open-label trial of Actimmune interferon γ-1b injection (rIFN-γ) for the treatment of metastatic renal cell carcinoma: favorable safety profile. Proc. Am. Soc. Clin. Oncol., 15: 259, 1996.
45. Lopez Hanninen, E., Kirchner, H., and Atzpodien, J. Interleukin-2-based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol., 155: 19-25, 1996.
46. Sella, A., Kilboum, R. G., Gray, I., Finn, L., Zukiwski, A. A., Ellerhorst, J., Amato, R. J., and Logothetis, C. J. Phase I study of interleukin-2 combined with interferon-α and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother., 9: 103-111, 1994.
47. Atzpodien, J., Kirchner, H., Hanninen, E. L., Deckert, M., Fenner, M., and Poliwoda, H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer, 29A(Suppl 5): S6-S8, 1993.
48. Bukowski, R. M., Sharfman, W., Murthy, S., Rayman, P., Tubbs, R., Alexander, J., Budd, G. T., Sergi, J. S., Bauer, L., Gibson, V., Stanley, J., Boyett, J., Pomes, E., and Finke, J. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res., 51: 4199-4205, 1991.
49. Figlin, R., Pierce, W. C., Kaboo, R., Tso, C. L., Moldawer, N., Dolan, N., Gitlitz, B., deKernion, J., and Belldegrun, A. Treatment of metastatic renal cell carcinoma with nephrectomy, interieukin-2 and cylokine-primed or CD8(+)-selected tumor-infiltrating lymphocytes from primary tumor, in press, 1997.
50. Graham, S., Babayan, R. K., Lamm, D. L., Sawczuk, I., Ross, S. D., Lavin, P. T., Osband, M. E., and Krane, R. J. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin. Urol., 11: 27-34, 1993.
51. Chang, A. E., Aruga, A., Cameron, M. J., Sondak, V. K., Normolle, D. P., Fox, B. A., and Shu, S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol., 15: 796-807, 1997.
52. Jaffee, E. M., Marshall, F., Weber, C., Pardoll, D. M., Levitsky, H., Nelson, W., Carducci, M., Mulligan, R., and Simons, J. Bioactivity of a human GM-CSF tumor vaccine for the treatment of metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 15: 237, 1996.
53. Vogelzang, N. J., Lestingi, T. M., Sudakoff, G., and Kradjian, S. A. Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum. Gene Ther., 5: 1357-1370, 1994.
54. Kranenborg, M. H., Boerman, O. C., Oosterwijk-Wakka, J. C., de Weijert, M. C., Corstens, F. H., and Oosterwijk, E. Development and characterization of anti-renal cell carcinoma × antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res., 55: 5864S-5867S, 1995.
55. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688-696, 1995.
56. Fyfe, G. A., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 14: 2410-2411, 1996.
57. Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P., and Fleischmann, J. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol., 154: 32-34, 1995.
58. Neidhart, J. A. Interferon therapy for the treatment of renal cancer. Cancer (Phila.), 57: 1696-1699, 1986.
59. Sarna, G., Figlin, R., and de Kernion, J. Interferon in renal cell carcinoma. The UCLA experience. Cancer (Phila.), 59: 610-612, 1987.
60. Muss, H. B., Costanzi, J. J., Leavitt, R., Williams, R. D., Kempf, R. A., Pollard, R., Ozer, H., Zekan, P. J., Grunberg, S. M., Mitchell, M. S., Caponera, M., Gavigan, M., Emest, M. L., Venturi, C., Greiner, J., and Spiegel, R. J. Recombinant α Interferon in renal cell carcinoma: a randomized trial of two routes of administration. J. Clin. Oncol., 5: 286-291, 1987.
61. Chikkala, N. F., Lewis, I., Ulchaker, J., Stanley, J., Tubbs, R., and Finke, J. H. Interactive effects of α-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res., 50: 1176-1182, 1990.
62. Pierce, W. C., Belldegrun, A., and Figlin, R. A. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal cell carcinoma. Semin. Oncol., 22: 74-80, 1995.
63. Bhardwaj, N., Young, J. W., Nisanian, A. J., Baggers, J., and Steinman, R. M. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J. Exp. Med., 778: 633-642, 1993.
64. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
65. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., and Mauri, F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen-presenting cells. Proc. Natl. Acad. Sci. USA, 92: 8078-8082, 1995.
66. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996.
67. Golumbek, P., Levitsky, H., Jaffee, L., and Pardoll, D. M. The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy. Immunol. Res., 12: 183-192, 1993.
68. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
69. Sun, W. H., Burkholder, J. K., Sun, J., Culp, J., Turner, J., Lu, X. G., Pugh, T. D., Ershler, W. B., and Yang, N. S. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc. Natl. Acad. Sci. USA, 92: 2889-2893, 1995.
70. Nabel, G. J., Yang, Z. Y., Nabel, E. G., Bishop, K., Marquet, M., Feigner, P. L., Gordon, D., and Chang, A. E. Direct gene transfer for treatment of human cancer. Ann. NY Acad. Sci., 772: 227-231, 1995.
71. Longo, D. L. Immunotherapy for non-Hodgkin's lymphoma. Curr. Opin. Oncol., 8: 353-359, 1996.
72. Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med., 2: 350-353, 1996.
73. Oosterwijk, E., de Weijert, M., van Bokhoven, A., Brakenhoff, R. H., Peelen, W. P., and Debruyne, F. M. Molecular characterization of the renal cell carcinoma-associated antigen G250. Proc. Am. Assoc. Cancer Res., 37: A3147, 1996.
74. Oosterwijk, E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O., Fleuren, G. J., Oettgen, H. F., and Old, L. J. Antibody localization in human renal cell carcinoma: a Phase I study of monoclonal antibody G250. J. Clin. Oncol., 11: 738-750, 1993.
75. Steffens, M. G., Boerman, O., Oosterwijk-Wakka, J. C., Oosterhof, G. O. N., Witjes, J. A., Koenders, E. B., Oyen, W. J. G., Buijs, W. C. A. M., Debruyne, F. M. J., Corstens, F. H. M., and Oosterwijk, E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 15: 1529-1537, 1997.
76. Rosenberg, S. A. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu. Rev. Med., 47: 481-491, 1996.